Adc Therapeutics Ltd (ADCT) Stock Analysis

AI analysis of Adc Therapeutics Ltd (ADCT)

Hold

ADC Therapeutics is currently a hold. The stock is priced at $1.54, significantly below its 52-week high of $4.98, indicating potential for recovery. However, the forward P/E ratio is currently at 0, reflecting uncertainty in future earnings. The recent workforce reduction is expected to save $10 million annually, which could improve financial stability, but the company reported a net income loss of $16.5 million in Q2 2026. The RSI is at 52.051, suggesting the stock is neither overbought nor oversold, indicating a neutral short-term outlook. The main risk is the significant insider selling, which has increased by 1160.65% over the last month, suggesting a lack of confidence from insiders.

Valuation Metrics

The current forward P/E ratio for Adc Therapeutics Ltd (ADCT) is 0.00, compared to its 5-year average forward P/E of -2.39.

Forward P/E

Overvalued

5Y Average P/E

-2.39

Current P/E

0.00

Overvalued

-0.36

Undervalued

-4.42

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-2.74

Current EV/EBITDA

-3.36

Overvalued

-0.13

Undervalued

-5.35

Forward P/S

Fair

5Y Average P/S

3.84

Current P/S

1.96

Overvalued

7.07

Undervalued

0.61

Alphio AI Price Scenarios for ADCT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ADCT

$3.35

Scenario price

B

Base

Base · 50%ADCT

$2.99

Scenario price

B

Bear

Bear · 25%ADCT

$2.82

Scenario price

Whales holding ADCT

T

TCG Crossover Management, LLC

+ HoldingADCT

-24.43%

3M Return

ADCT FAQ — answered by Alphio AI

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ADC Therapeutics is currently a hold. The stock is priced at $1.54, significantly below its 52-week high of $4.98, indicating potential for recovery. However, the forward P/E ratio is currently at 0, reflecting uncertainty in future earnings. The recent workforce reduction is expected to save $10 million annually, which could improve financial stability, but the company reported a net income loss of $16.5 million in Q2 2026. The RSI is at 52.051, suggesting the stock is neither overbought nor oversold, indicating a neutral short-term outlook. The main risk is the significant insider selling, which has increased by 1160.65% over the last month, suggesting a lack of confidence from insiders.